FAIRFIELD, CT / ACCESSWIRE / November 6, 2019 / Calmare Therapeutics Incorporated, (OTC PINK:CTTC) ("CTI"), the pain mitigation company ("Calmare"), has $841,673.85 judgment vacated by the United States Court of Appeals for the Second Circuit (the "Court").
On September 29, 2017, the District Court of Connecticut entered a final judgment awarding GEOMC Co. Ltd. - a South Korea corporation - attorneys' fees in the amount of $836,442.05 and costs in the amount of $5,231.80 totaling $841.673.85 stemming from a complaint filed on August 22, 2014. Calmare appealed the ruling.
On October 30, 2019, the United States Court of Appeals for the Second Circuit vacated the District Court's May 25, 2018 order awarding GEOMC attorneys' fees and costs, and remanded the case to the District Court for further proceedings.
"This overturning is one more step to help clear the path for further development of the Company's business," said Calmare Therapeutics President & CEO Conrad Mir.
About Calmare Therapeutics, Inc.
Calmare Therapeutics, Inc. researches, develops and commercializes chronic, neuropathic pain and wound affliction devices. Our flagship medical device - the Calmare® Pain Therapy Device (the "Calmare Device") - is the world's only non-invasive and non-addictive modality that can successfully treat chronic, neuropathic pain. The Company holds a U.S. Food & Drug Administration 510k clearance designation on its flagship device, which grants it the exclusive right to sell, market, research and develop the medical device in the United States. The Calmare Devices are commercially sold to medical practices throughout the world. They are also found in U.S. military hospitals, clinics and on installations.
Forward-Looking Statement
Certain statements contained in this press release are forward-looking statements that involve risks and uncertainties. The statements contained herein that are not purely historical are forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements deal with the Company's current plans, intentions, beliefs and expectations and statements of future economic performance. Forward-looking statements involve known and unknown risks and uncertainties that may cause the Company's actual results in future periods to differ materially from what is currently anticipated. Factors that could cause or contribute to such differences include those discussed from time to time in reports filed by the Company with the Securities and Exchange Commission. The Company cannot guarantee its future results, levels of activity, performance or achievements.
Contacts:
Calmare Therapeutics Incorporated
Conrad Mir
President and CEO
cmir@calmaretherapeutics.com
203.368.6044
www.calmaretherapeutics.com
SOURCE: Calmare Therapeutics Incorporated
View source version on accesswire.com:
https://www.accesswire.com/565469/Calmare-Therapeutics-Has-842000-Judgment-Vacated-by-the-US-Court-Of-Appeals-for-the-Second-Circuit